Unlocking COVID therapeutic targets: A structure-based rationale against SARS-CoV-2, SARS-CoV and MERS-CoV Spike
There are no approved target therapeutics against SARS-CoV-2 or other beta-CoVs. The beta-CoV Spike protein is a promising target considering the critical role in viral infection and pathogenesis and its surface exposed features. We performed a structure-based strategy targeting highly conserved druggable regions resulting from a comprehensive large-scale sequence analysis and structural characterization of Spike domains across SARSr- and MERSr-CoVs. We have disclosed 28 main consensus druggable pockets within the Spike. The RBD and SD1 (S1 subunit); and the CR, HR1 and CH (S2 subunit) represent the most promising conserved druggable regions. Additionally, we have identified 181 new potential hot spot residues for the hSARSr-CoVs and 72 new hot spot residues for the SARSr- and MERSr-CoVs, which have not been described before in the literature. These sites/residues exhibit advantageous structural features for targeted molecular and pharmacological modulation. This study establishes the Spike as a promising anti-CoV target using an approach with a potential higher resilience to resistance development and directed to a broad spectrum of Beta-CoVs, including the new SARS-CoV-2 responsible for COVID-19. This research also provides a structure-based rationale for the design and discovery of chemical inhibitors, antibodies or other therapeutic modalities successfully targeting the Beta-CoV Spike protein..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Computational and Structural Biotechnology Journal - 18(2020), Seite 2117-2131 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
João Trigueiro-Louro [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Betacoronavirus |
|---|
| doi: |
10.1016/j.csbj.2020.07.017 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ058977562 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ058977562 | ||
| 003 | DE-627 | ||
| 005 | 20230502101337.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230228s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.csbj.2020.07.017 |2 doi | |
| 035 | |a (DE-627)DOAJ058977562 | ||
| 035 | |a (DE-599)DOAJa92e138139094ccea9f09fa631c8d277 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a TP248.13-248.65 | |
| 100 | 0 | |a João Trigueiro-Louro |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Unlocking COVID therapeutic targets: A structure-based rationale against SARS-CoV-2, SARS-CoV and MERS-CoV Spike |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a There are no approved target therapeutics against SARS-CoV-2 or other beta-CoVs. The beta-CoV Spike protein is a promising target considering the critical role in viral infection and pathogenesis and its surface exposed features. We performed a structure-based strategy targeting highly conserved druggable regions resulting from a comprehensive large-scale sequence analysis and structural characterization of Spike domains across SARSr- and MERSr-CoVs. We have disclosed 28 main consensus druggable pockets within the Spike. The RBD and SD1 (S1 subunit); and the CR, HR1 and CH (S2 subunit) represent the most promising conserved druggable regions. Additionally, we have identified 181 new potential hot spot residues for the hSARSr-CoVs and 72 new hot spot residues for the SARSr- and MERSr-CoVs, which have not been described before in the literature. These sites/residues exhibit advantageous structural features for targeted molecular and pharmacological modulation. This study establishes the Spike as a promising anti-CoV target using an approach with a potential higher resilience to resistance development and directed to a broad spectrum of Beta-CoVs, including the new SARS-CoV-2 responsible for COVID-19. This research also provides a structure-based rationale for the design and discovery of chemical inhibitors, antibodies or other therapeutic modalities successfully targeting the Beta-CoV Spike protein. | ||
| 650 | 4 | |a Betacoronavirus | |
| 650 | 4 | |a Coronavirus disease | |
| 650 | 4 | |a Druggability prediction | |
| 650 | 4 | |a Novel antiviral targets | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Sequence conservation | |
| 653 | 0 | |a Biotechnology | |
| 700 | 0 | |a Vanessa Correia |e verfasserin |4 aut | |
| 700 | 0 | |a Inês Figueiredo-Nunes |e verfasserin |4 aut | |
| 700 | 0 | |a Marta Gíria |e verfasserin |4 aut | |
| 700 | 0 | |a Helena Rebelo-de-Andrade |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Computational and Structural Biotechnology Journal |d Elsevier, 2013 |g 18(2020), Seite 2117-2131 |w (DE-627)DOAJ00005383X |x 20010370 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2020 |g pages:2117-2131 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.csbj.2020.07.017 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/a92e138139094ccea9f09fa631c8d277 |z kostenfrei |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S2001037020303494 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2001-0370 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2020 |h 2117-2131 | ||